Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Policies

UCL Enterprise will place details on this page of UCL policies in relation to commercial and knowledge transfer activities where a public statement of those policies is desirable. Internal policies in these areas will be documented as appropriate elsewhere and in password-protected areas where needed.

Equitable Dissemination of Medical Technologies
PDF, 127.6KB